- Imugene (IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at the 2022 Study of Lung Cancer annual conference in Vienna
- The presentation was presented by Professor Michael Boyer of the Chris O’Brien Lifehouse Hospital
- The study was trialling its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer
- CEO and Managing Director Leslie Chong says the company is encouraged seeing “positive signals” with correlative biomarker data at such an early stage of the PD1-Vaxx phase one trial
- Shares in Imugene are up 5.77 per cent to 27.5 cents per share as of 1:02 pm AEST
Imugene (IMU) presented new data from its PD1-Vaxx trial in non-small cell lung cancer patients at the International Association for the Study of Lung Cancer’s annual conference in Vienna.
The presentation was presented by Professor Michael Boyer of the Chris O’Brien Lifehouse Hospital.
The study was trialling its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer.
CEO and Managing Director Leslie Chong said the company is encouraged seeing “positive signals” with correlative biomarker data at such an early stage of the PD1-Vaxx
Phase I trial.
“We are now progressing to the Phase 1b combination studies in treatment naive patients.
“It’s particularly gratifying to have followed a patient in the trial for over 18 months where their tumour burden has been reduced to zero.
“For such a late-stage patient, having a chemo-free alternative could mean a very real difference to their quality of life.”
The phase one trial included different doses, with four patients were in the 10 micrograms per dose cohort, with one patients achieved a complete response, meaning all signs of cancer disappeared due to the treatment.
In the six patient 50 microgram dose cohort, two achieved stable disease, meaning the tumour neither shrunk or grew.
While out of the four patients who received 100-microgram dose
By week six, antibodies to IMU-201 were generated and sustained at high titers during treatment with 100 micrograms of PD1-Vaxx, with a dose dependent increase in antibody production in patients receiving the 100 microgram dose.
Taken together, these data support further evaluation of IMU-201 in NSCLC.
Shares in Imugene were up 5.77 per cent to 27.5 cents per share as of 1:02 pm AEST.